Insider Buying: Standard BioTools Inc. (NASDAQ:LAB) Director Buys 4,820,959 Shares of Stock

Standard BioTools Inc. (NASDAQ:LAB - Get Free Report) Director Casdin Partners Master Fund, L bought 4,820,959 shares of the business's stock in a transaction on Friday, February 28th. The stock was bought at an average cost of $1.06 per share, with a total value of $5,110,216.54. Following the transaction, the director now owns 58,846,780 shares in the company, valued at $62,377,586.80. This trade represents a 8.92 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Standard BioTools Trading Up 2.7 %

NASDAQ:LAB traded up $0.03 during trading hours on Friday, reaching $1.16. The company had a trading volume of 3,709,846 shares, compared to its average volume of 2,176,444. Standard BioTools Inc. has a 52 week low of $0.99 and a 52 week high of $3.04. The firm's 50 day moving average price is $1.52 and its 200-day moving average price is $1.78. The firm has a market cap of $431.82 million, a price-to-earnings ratio of -1.63 and a beta of 1.62.

Institutional Investors Weigh In On Standard BioTools

Hedge funds have recently modified their holdings of the business. Wolverine Trading LLC bought a new stake in shares of Standard BioTools during the 3rd quarter valued at $27,000. Takeda Pharmaceutical Co. Ltd. bought a new stake in shares of Standard BioTools during the 4th quarter valued at $29,000. Two Sigma Securities LLC bought a new stake in shares of Standard BioTools during the 4th quarter valued at $30,000. Nisa Investment Advisors LLC grew its position in shares of Standard BioTools by 433.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company's stock valued at $35,000 after acquiring an additional 14,732 shares during the period. Finally, Creative Planning bought a new stake in shares of Standard BioTools during the 3rd quarter valued at $39,000. Institutional investors own 53.74% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Separately, KeyCorp downgraded shares of Standard BioTools from an "overweight" rating to a "sector weight" rating in a research report on Thursday, February 27th.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.